Citius Pharmaceuticals- Warrants(02/08/2022) Net Income

Citius Pharmaceuticals- Warrants(02/08/2022) (CTXRW) currently reports a net income of $-57M as of June 2026. That compares with $-41M in the prior-year period — down 40.4% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Citius Pharmaceuticals- Warrants(02/08/2022)'s net income history and peer comparisons.

Citius Pharmaceuticals- Warrants(02/08/2022)'s net income decreased from $-41M to $-57M — a 40.4% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Citius Pharmaceuticals- Warrants(02/08/2022)'s net income of $-57M is lower than the Healthcare sector average of $16B. That is roughly 100.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Citius Pharmaceuticals- Warrants(02/08/2022) reported $-57M in net income as of June 2026. That compares with $-41M in the prior-year period — down 40.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-57M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Citius Pharmaceuticals- Warrants(02/08/2022), and consider following CTXRW for alerts when major investors trade the stock.